Safety pharmacology evaluation makes it possible to clarify the potential adverse effects of novel cardiovascular drugs on physiologic function at dosage within or above the therapeutic range. Ace Therapeutics provides comprehensive preclinical cardiovascular safety pharmacology evaluation services to help determine whether the drug candidate has potential adverse effect in the early stages of drug development.
Effective cardiac safety pharmacology evaluation in the early stages of drug development is an important study for the forward development of drug candidates. In terms of evaluating the potential arrhythmogenic effects of drugs, the main evaluation methods include in vitro detection of the blocking effect of drugs on hERG currents on non-human cardiomyocytes or tissues, and in vivo experiments to detect the effect of drugs on the prolongation of QT intervals on the electrocardiogram in animals.
Fig. 1 Types of immune checkpoint inhibitor-associated immune-related adverse events. (Baik AH, et al. 2021)
Ace Therapeutics can evaluate the potential adverse effects of tested cardiovascular drugs in experimental animals. If there are doubts about the results that may affect human safety, additional safety pharmacology evaluation should be conducted. The following is a list of evaluation contents we can provide.
| For Cardiovascular System | For Central Nervous System | For Respiratory System | |
|---|---|---|---|
| Core Battery Safety Pharmacology Evaluation | We can evaluate the adverse effects of tested drugs on the cardiovascular system, including blood pressure, heart rate, and electrocardiogram, to determine the risk of the tested drug on ventricular repolarization and arrhythmogenicity. | We can evaluate the adverse effects of tested drugs on the central nervous system, including motor function, behavioral changes, and motor reflexes by using the Irwin test in mice or the functional observation bundle (FOB) test in rats. | The adverse effects of tested drug on the respiratory system can be evaluated by measuring the respiratory rate and other indicators of respiratory function in experimental animals. |
| Supplemental Safety Pharmacology Evaluation | We can explore in depth the adverse effects of the tested drug on cardiac output, myocardial contractility, vascular resistance and other cardiovascular indicators. | We can conduct in-depth tests on the behavior, learning memory, neuro-biochemistry, vision, hearing and/or electrophysiology of experimental animals. | We can analyze in depth the indexes of airway resistance, pulmonary artery pressure, and blood gas analysis of experimental animals. |
Ace Therapeutics is a contract research organization specializing in drug development of cardiovascular diseases. With our professional research platform and research team, we can provide preclinical safety pharmacology evaluation services for cardiovascular drugs according to clients' needs. If you are interested in our services, please don't hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.